Scan: Will Trump make IVF free?

← Back to scans

Will Trump make IVF free? — Before 2029

KXFREEIVF-29 · Health · 2026-04-29

14%

Agent

16%

Market Price

-2.0%

Edge

50%

Confidence

Volume: 33,699

Spread: 1.0c

Days to resolution: 996

Markets in event: 1

Final Rationale

My independent 10.3% estimate was anchored on Trump's clear pattern of voluntary/discount approaches (EO 14216 study-only, October 2025 EMD Serono 84% discount, NDAA IVF coverage stripped Dec 2025) rather than mandates that eliminate cost. I PARTIALLY ACCEPT the critic's combination-method challenge — sq2 and sq3 are partially disjunctive YES paths and weighted-averaging understates their union, which alone justifies moving toward ~13-15%. I REJECT the strongest framing of Challenge 1 (broad resolution interpretation) since 'eliminates the cost of at least one IVF cycle' is a high bar that the EMD Serono discount and voluntary employer guidance clearly fail, but accept that a VA/TRICARE/FEHB expansion path adds modest probability mass. The market at 16% sits just above my corrected estimate; with 33 months remaining and low-liquidity pricing (extreme bid/ask spread), I land at 14% — close to but slightly below market because concrete legislative/EO momentum remains absent as of April 2026.

Price vs. prediction

How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.

$n = 58$ follow-ups

Re-scan Context

This market has been scanned before. Previous predictions:

Date	Predicted	Market Price	Confidence
2026-04-03	10%	16%	50%

1. Planner Opus · Fermi decomposition + tool plan

Tools chosen: kalshi_data kalshi_orderbook article_search web_search congress_bills wikipedia_lookup

Sub-questions (Fermi decomposition)

Has Trump already taken any executive action or signed legislation that would make at least one IVF cycle free for Americans? (w=0.15)
Will Congress pass legislation mandating IVF coverage or federal subsidization that Trump would sign before January 2029? (w=0.40)
Will Trump use executive action (executive order, agency rulemaking, or federal program expansion) to eliminate the cost of at least one IVF cycle before January 2029? (w=0.30)
Does Trump have sufficient political motivation and Republican coalition support to prioritize IVF cost elimination before the 2026 midterms or during his remaining term? (w=0.15)

Planner reasoning

Trump made IVF access a campaign talking point in 2024, promising to 'make IVF free' via government or insurance mandates. The key questions are: (1) What specific mechanism would be used — executive action vs. legislation? (2) Has anything already happened? (3) What is the legislative pathway given Republican coalition tensions between pro-IVF and anti-IVF (embryo personhood) factions? Reference class: Trump has a pattern of making sweeping healthcare promises but delivering less. The ACA repeal failed; drug pricing had limited success. However, IVF is politically popular (bipartisan support among voters), reducing opposition. The Senate IVF bill failed in 2024 when Democrats tried to force a vote, but Republicans blocked it for procedural/political reasons, not because they oppose IVF in principle. Causal mechanisms: (1) Executive path — Trump could issue an EO requiring federal employee insurance to cover IVF, or expand VA/Medicaid coverage, which would qualify as 'eliminating cost' for at least one IVF cycle for some Americans. This is the most plausible near-term mechanism. (2) Legislative path — Congress could pass an IVF mandate bill; this is harder given Senate filibuster dynamics and intra-party tensions around embryo status. Temporal analysis: ~996 days remain. For YES to occur: Trump or Congress must act in the next ~33 months. The political window is most open in 2025-early 2026 (pre-midterm), as Trump's leverage diminishes after midterms regardless of outcome. An EO could happen at any time Trump chooses. Legislation would require months of committee work, floor votes, and reconciliation. The Trump EO path is faster but may cover only federal employees/programs rather than all Americans — the resolution criteria says 'eliminates cost of at least one IVF cycle,' which could be interpreted broadly (for any American) or narrowly (for some defined class). Key uncertainty: Does an EO covering federal employees count? Does expanding VA IVF benefits count? The resolution language says 'the President takes an action that eliminates the cost' — this suggests any action, even if covering a subset of Americans. This broadens the YES probability meaningfully. Base rate consideration: Presidential campaign health promises that become policy within one term: ~20-40% base rate for specific policy items. IVF has higher probability than most due to bipartisan voter support and Trump's explicit promise.

2. Research Parallel tool calls · legacy v2

Tool	Status	Time	Items
kalshi_data	OK	2.0s	-
kalshi_orderbook	OK	0.2s	-
article_search	OK	0.9s	-
web_search	OK	64.7s	-
congress_bills	OK	0.7s	-
wikipedia_lookup	OK	1.2s	-

3. Evidence Synthesis Sonnet · 18 items · legacy v2

#	Strength	Credibility	Direction	Source	Claim	Priced In
1	STRONG	88	↓ DOWN	web_search	Trump signed Executive Order 14216 on February 18, 2025, directing policy recommendations for reducing IVF out-of-pocket costs, but this EO did not itself make IVF free or mandate coverage.	Yes
2	STRONG	82	↓ DOWN	web_search	The 90-day deadline for IVF policy recommendations under EO 14216 passed in May 2025 with no results released; the White House provided no timeline for findings.	Yes
3	STRONG	85	↓ DOWN	web_search	On October 16, 2025, the Trump administration announced a deal with EMD Serono for an 84% discount on common IVF medications (saving up to $2,200/cycle), and voluntary employer guidance on fertility benefits — but did not make IVF free or mandatory.	Yes
4	MODERATE	72	↓ DOWN	article_search	As of late April 2026, there is no evidence in available articles that Trump has signed any legislation or EO that eliminates the cost of at least one IVF cycle for any class of Americans.	Yes
5	MODERATE	65	↓ DOWN	kalshi_data	The Kalshi market for 'Will Trump make IVF free before 2029' is priced at 16%, suggesting market participants do not believe this has already occurred.	Yes
6	STRONG	87	↓ DOWN	article_search	IVF coverage for military families was cut from the NDAA defense bill in December 2025 (House passed the $901B bill without it), despite earlier inclusion in both House and Senate versions.	Yes
7	MODERATE	60	↓ DOWN	congress_bills	No IVF-related legislation was found in the congressional bill search results; no bill mandating IVF coverage or federal subsidization appears to be advancing.	Yes
8	MODERATE	68	↓ DOWN	article_search	As of April 2026, Congress is focused on immigration, government funding, elections legislation (SAVE Act), and Iran war authorization — IVF legislation is not a visible legislative priority.	Yes
9	MODERATE	65	↓ DOWN	article_search	Trump's political difficulties (falling approval ratings due to Iran war, deportation crackdown, inflation) reduce political capital available for domestic social legislation like IVF mandates.	No
10	STRONG	85	↑ UP	wikipedia_lookup	Trump explicitly promised during his 2024 campaign to 'make IVF free' via government or insurance mandates, establishing political motivation for action.	Yes
11	STRONG	84	↓ DOWN	web_search	The October 2025 drug discount deal (84% off IVF medications via EMD Serono) and voluntary employer guidance represent the most concrete executive action to date, but fall far short of eliminating IVF costs.	Yes
12	STRONG	84	↓ DOWN	web_search	The DOL/HHS/Treasury guidance issued in October 2025 authorizes but does not require employers to offer fertility benefits, making coverage entirely voluntary — not eliminating cost for any defined class.	Yes
13	MODERATE	65	↓ DOWN	article_search	No evidence found of Trump expanding VA IVF benefits, issuing a new EO mandating coverage, or taking any executive action since October 2025 that would eliminate IVF costs for any group.	Yes
14	MODERATE	70	↓ DOWN	web_search	The EO 14216 framework shows Trump prefers voluntary, market-negotiated approaches (drug discounts, employer opt-in guidance) rather than mandates, suggesting future executive action is unlikely to meet 'eliminates cost' threshold.	No
15	MODERATE	70	↓ DOWN	article_search	Trump's approval ratings are cratering as of April 2026 due to the Iran war, deportation crackdown, and inflation — reducing his political leverage and ability to push new domestic priorities.	No
16	WEAK	50	↑ UP	article_search	The midterms are approaching (2026), which could create some incentive to deliver on IVF promise to appeal to suburban voters, but legislative bandwidth is consumed by other priorities.	Yes
17	STRONG	85	↓ DOWN	article_search	Congressional Republicans stripped IVF military coverage from the NDAA in December 2025, suggesting intra-party resistance to IVF mandates even in narrow contexts (military families).	Yes
18	WEAK	50	↓ DOWN	article_search	Congress is yielding power to Trump on major issues (Iran war, immigration), but no evidence IVF has become a legislative priority or received active White House lobbying.	Yes

Information Gaps

No data on whether the IVF drug discount deal (October 2025) with EMD Serono qualifies under the resolution criteria — does a medication cost reduction alone constitute 'eliminating the cost of at least one IVF cycle'?
No information on current White House domestic policy agenda for 2026-2028 regarding IVF specifically
No data on whether VA IVF benefit expansions have been proposed or implemented via executive rulemaking
No information on whether the reconciliation/Big Beautiful Bill process includes any IVF provisions
No market research on whether federal employee FEHB (Federal Employees Health Benefits) IVF coverage has been expanded by executive action
No reporting on the current status of IVF-related legislation in Congress after December 2025 NDAA failure
Missing information on resolution criteria interpretation: would covering federal employees or military families alone qualify as 'eliminates cost for at least one IVF cycle'?
No data from 2026 on whether any new executive actions on IVF have been taken between October 2025 and April 2026

Key Uncertainties

Resolution criteria ambiguity: Does partial coverage (federal employees, military, Medicaid expansion) count as 'eliminates cost of at least one IVF cycle' for resolution purposes?
Whether escalating political difficulties (Iran war, inflation) cause Trump to seek a popular domestic win on IVF vs. deplete all political capital
Whether intra-Republican tension over embryo personhood can be overcome for any IVF mandate legislation
Whether the voluntary employer guidance framework could be converted to a mandate via agency rulemaking (ERISA, ACA mechanisms)
Whether a future EO expanding VA or TRICARE IVF benefits would qualify for resolution
Whether Trump's declining approval ratings make him more or less likely to pursue high-profile domestic promises like IVF before 2026 midterms
Whether budget reconciliation (if pursued) could include IVF subsidy provisions

Market Context

Price: 0.16 · 7d: +0.02 · 30d: +0.01
Volume: LOW-MODERATE — 159 avg daily contracts · Depth: HIGH — depth of 28,562 contracts, but spread of $0.98 is extremely wide suggesting low liquidity at executable prices
Reliability: LOW-MEDIUM — high contract depth but extreme spread ($0.01 bid/$0.01 ask) suggests the orderbook data may be unreliable or stale; the 16% price reflects modest but real market skepticism about resolution before 2029

4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price

Independent estimate: 10% (60% confidence)

base rate

10%

60% conf

evidence driven

10%

60% conf

contrarian

11%

60% conf

Spread

1pp

Low disagreement

sq1: Has Trump already taken any executive action or signed legislation that would make at least one IVF cycle free for Americans?

Base rate for 'already happened' questions is binary based on evidence. EO 14216 (Feb 2025) only directed policy recommendations. The Oct 2025 EMD Serono deal provides 84% discount on medications (not free, not full cycle). Voluntary employer guidance does not eliminate cost. No evidence of any action that 'eliminates the cost of at least one IVF cycle.' Small residual probability for ambiguous resolution interpretation of the drug discount.

sq2: Will Congress pass legislation mandating IVF coverage or federal subsidization that Trump would sign before January 2029?

Base rate for major healthcare mandate legislation passing Congress in any 3-year window: ~10-15%. Strong evidence pushing DOWN: IVF coverage was stripped from NDAA in Dec 2025 (showing GOP resistance even for narrow military families coverage), no IVF bills advancing as of April 2026, intra-GOP embryo personhood tension, filibuster constraints, Trump's declining political capital, and crowded legislative agenda. Slight UP from Trump's campaign promise. Net: ~7%.

sq3: Will Trump use executive action to eliminate the cost of at least one IVF cycle before January 2029?

18%

Base rate for executive actions delivering on specific campaign healthcare promises: ~20-30%. Trump has shown clear preference for voluntary/market approaches (drug discounts, employer opt-in) rather than mandates. However, ~33 months remain and Trump could expand VA/TRICARE/FEHB IVF benefits via executive action — this is a relatively easy path that could qualify under broad resolution interpretation. Key uncertainty: whether resolution counts narrow class coverage. Existing actions fall short. Pushing DOWN: declining approval, no signals of imminent action, EO 14216 deadline already missed. Estimate ~18% accounting for time remaining and possibility of a federal-employee or veterans IVF benefit expansion that could qualify.

sq4: Does Trump have sufficient political motivation and coalition support to prioritize IVF cost elimination?

20%

Trump made the campaign promise but has not visibly prioritized it. Cratering approval ratings could go either way — could push him to seek popular wins, or deplete political capital entirely. NDAA IVF stripping shows GOP coalition resistance. Bandwidth consumed by Iran war, immigration, inflation. Some residual motivation from midterms and legacy concerns. ~20%.

Show full reasoning trace

base rate: Presidential campaign-specific healthcare promises delivered within one term: ~20-30% base rate. However, IVF 'free' is a particularly ambitious commitment requiring either mandate legislation (rare, contested) or executive action with limited reach. Adjusted base rate ~15-20%.

evidence updates: Strong DOWN updates: EO 14216 was study-only, 90-day deadline missed, October 2025 actions are voluntary/discount-based not free, NDAA IVF coverage stripped Dec 2025, no IVF bills advancing, Trump approval cratering, administration explicitly preferring market approaches. Modest UP: campaign promise creates motivation, ~33 months remain, executive action path exists for narrow coverage.

combination method: Weighted average across four sub-questions, with sq3 (executive action) and sq2 (legislation) as the dominant paths. Adjusted slightly downward for positive correlation among factors.

final: Trump's pattern is voluntary/market approaches rather than mandates eliminating costs. The most plausible YES path is an executive expansion of VA/TRICARE/FEHB IVF benefits that meets a broad reading of 'eliminates cost,' but no signals this is imminent. With 33 months remaining there's meaningful residual probability. Final: 10%.

ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.1, 'confidence': 0.6}, 'evidence_driven': {'p_yes': 0.1, 'confidence': 0.6}, 'contrarian': {'p_yes': 0.11, 'confidence': 0.6}}, 'spread': 0.01, 'individual_p_yes': {'base_rate': 0.1, 'evidence_driven': 0.1, 'contrarian': 0.11}}

5. Devil's Advocate Sonnet · legacy v2 Market price revealed

Asymmetric Evidence Reasoning Flaw Missing Info

Challenges

Resolution criteria ambiguity is under-weighted. The forecaster acknowledges in info gaps that it's unclear whether VA/TRICARE/FEHB expansion or even the EMD Serono 84% discount could qualify under a broad reading, but then assigns only 5% to sq1 and 18% to sq3. With 33 months remaining and Trump's clear pattern of claiming 'wins' via voluntary/discount approaches, the probability that SOME action gets framed/resolved as 'making IVF free' deserves more weight — especially given Polymarket-style resolution often hinges on subjective adjudication.
Sub-question combination appears to double-count downside. sq2 (legislation), sq3 (executive action), and sq4 (political will) are not independent — sq4 partially drives sq2 and sq3. Multiplying or weighted-averaging all four risks compounding the same negative signal. The cleaner decomposition is P(YES) = P(sq1) + P(not sq1) * [P(legislation) + P(not legislation) * P(qualifying EO)], which with 7% + 18% rough independent paths yields ~24%, not 10%.
33 months is a long horizon and the forecast may be over-anchored on the present moment's lack of momentum. Healthcare deliverables often cluster pre-midterm or pre-reelection-legacy windows; the forecaster notes midterm incentive but only as WEAK UP. A pre-2026-midterm or 2028-legacy push is a non-trivial scenario.
The forecaster treats Trump's declining approval as a DOWN factor, but politically weak presidents often pursue cheap symbolic wins via executive action precisely when legislation stalls. This could be neutral or mildly UP for sq3, not DOWN.
Confidence of 0.6 with 996 days remaining and acknowledged resolution ambiguity seems too high. The information gaps listed are substantial and should widen uncertainty.

Suggested adjustment: +4pp

Adjust upward modestly (~14%) to correct for (1) likely double-counting of correlated negative factors across sub-questions, (2) under-weighting of resolution-criteria ambiguity given the long time horizon, and (3) failure to properly account for the disjunctive nature of YES paths (legislation OR qualifying EO OR broad-resolution interpretation of voluntary actions). This is not a recommendation to converge to the market — it's a correction for combination-method error.

Market comparison: Forecaster: 10.3%, Market: 16%. The 5.7pp divergence is modest and the market has low liquidity (extreme bid/ask spread). The market price likely reflects similar reasoning plus a small premium for resolution ambiguity and tail scenarios. After correcting for the combination-method issue, the gap largely closes — not because the market is right, but because the forecaster's decomposition under-counted disjunctive YES paths.

6. Aggregator Opus · final calibrated forecast

14% (50% confidence)